Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ACAD's Cash-to-Debt is ranked higher than
97% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. NAS:ACAD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ACAD' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.56  Med: 337.16 Max: 98090
Current: No Debt
5.56
98090
Equity-to-Asset 0.94
NAS:ACAD's Equity-to-Asset is ranked higher than
93% of the 483 Companies
in the Global Biotechnology industry.

( Industry Median: 0.63 vs. NAS:ACAD: 0.94 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ACAD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.13  Med: 0.78 Max: 0.98
Current: 0.94
-2.13
0.98
Interest Coverage No Debt
NAS:ACAD's Interest Coverage is ranked higher than
98% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:ACAD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ACAD' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 4
Altman Z-Score: 69.74
Beneish M-Score: 52.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -4458.76
NAS:ACAD's Operating Margin % is ranked lower than
89% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -50.65 vs. NAS:ACAD: -4458.76 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ACAD' s Operating Margin % Range Over the Past 10 Years
Min: -269855.74  Med: -967.44 Max: 35.82
Current: -4458.76
-269855.74
35.82
Net Margin % -4427.79
NAS:ACAD's Net Margin % is ranked lower than
90% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -43.94 vs. NAS:ACAD: -4427.79 )
Ranked among companies with meaningful Net Margin % only.
NAS:ACAD' s Net Margin % Range Over the Past 10 Years
Min: -269578.69  Med: -923.87 Max: 35.93
Current: -4427.79
-269578.69
35.93
ROE % -64.13
NAS:ACAD's ROE % is ranked lower than
69% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. NAS:ACAD: -64.13 )
Ranked among companies with meaningful ROE % only.
NAS:ACAD' s ROE % Range Over the Past 10 Years
Min: -138.68  Med: -63.43 Max: 72.43
Current: -64.13
-138.68
72.43
ROA % -59.94
NAS:ACAD's ROA % is ranked lower than
73% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. NAS:ACAD: -59.94 )
Ranked among companies with meaningful ROA % only.
NAS:ACAD' s ROA % Range Over the Past 10 Years
Min: -78.95  Med: -54.79 Max: 34.38
Current: -59.94
-78.95
34.38
ROC (Joel Greenblatt) % -9272.16
NAS:ACAD's ROC (Joel Greenblatt) % is ranked lower than
87% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. NAS:ACAD: -9272.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ACAD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -21643.52  Med: -5397.08 Max: 2028.76
Current: -9272.16
-21643.52
2028.76
3-Year Revenue Growth Rate -77.60
NAS:ACAD's 3-Year Revenue Growth Rate is ranked lower than
89% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:ACAD: -77.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ACAD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -77.6  Med: -45.6 Max: 71.7
Current: -77.6
-77.6
71.7
3-Year EBITDA Growth Rate 62.90
NAS:ACAD's 3-Year EBITDA Growth Rate is ranked higher than
93% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. NAS:ACAD: 62.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ACAD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53  Med: -12.2 Max: 62.9
Current: 62.9
-53
62.9
3-Year EPS without NRI Growth Rate 62.50
NAS:ACAD's 3-Year EPS without NRI Growth Rate is ranked higher than
94% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:ACAD: 62.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ACAD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.6  Med: -9.3 Max: 62.5
Current: 62.5
-36.6
62.5
GuruFocus has detected 6 Warning Signs with ACADIA Pharmaceuticals Inc $NAS:ACAD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ACAD's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ACAD Guru Trades in Q1 2016

Steven Cohen 2,222,700 sh (+631.63%)
Steven Cohen 450,000 sh (unchged)
Ron Baron Sold Out
Paul Tudor Jones Sold Out
Louis Moore Bacon Sold Out
» More
Q2 2016

ACAD Guru Trades in Q2 2016

Steven Cohen 1,199,700 sh (-46.03%)
» More
Q3 2016

ACAD Guru Trades in Q3 2016

George Soros 17,645 sh (New)
Jana Partners 149,252 sh (New)
Steven Cohen 2,071,500 sh (+72.67%)
Steven Cohen 120,300 sh (unchged)
» More
Q4 2016

ACAD Guru Trades in Q4 2016

Joel Greenblatt 25,682 sh (New)
Jana Partners 301,243 sh (+101.84%)
George Soros Sold Out
Steven Cohen 1,225,000 sh (-40.86%)
» More
» Details

Insider Trades

Latest Guru Trades with ACAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ARIA, NAS:IONS, NAS:ALNY, NAS:TECH, NAS:BLUE, NAS:RARE, NAS:EXEL, OTCPK:GLPGF, NAS:CBPO, NAS:ICPT, NAS:UTHR, OTCPK:BTGGF, NAS:CLVS, NAS:SAGE, OTCPK:ABCZF, NAS:LGND, NAS:NKTR, NAS:AGIO, NAS:ONCE, NYSE:CBM » details
Traded in other countries:DR6.Germany,
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

ACADIA Pharmaceuticals Inc was incorporated in Vermont in 1993 as Receptor Technologies, Inc. The Company reincorporated in Delaware in 1997. It is a biopharmaceutical Company engaged in the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Pimavanserin is a new chemical entity that the Company discovered and has advanced to Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Parkinsons disease psychosis is a debilitating disorder that develops in up to 60 percent of patients with Parkinsons disease. The Company has completed a Phase II trial with pimavanserin as a co-therapy in schizophrenia and has established plans for a future Phase II feasibility study to explore the use of pimavanserin as a treatment for Alzheimers disease psychosis. In collaboration with Allergan, it has discovered and is developing small molecule product candidates for the treatment of chronic pain. Chronic pain is a common form of persistent pain that may be related to a number of medical conditions and is often resistant to treatment. Allergan has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome. The Company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. This program has reached Phase I development. ACADIA and R-SAT are company's registered trademarks. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. It is subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.

Ratios

vs
industry
vs
history
PB Ratio 8.15
ACAD's PB Ratio is ranked lower than
77% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. ACAD: 8.15 )
Ranked among companies with meaningful PB Ratio only.
ACAD' s PB Ratio Range Over the Past 10 Years
Min: 0.48  Med: 5.44 Max: 16.67
Current: 8.15
0.48
16.67
PS Ratio 845.22
ACAD's PS Ratio is ranked lower than
97% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. ACAD: 845.22 )
Ranked among companies with meaningful PS Ratio only.
ACAD' s PS Ratio Range Over the Past 10 Years
Min: 0.64  Med: 47.45 Max: 39600
Current: 845.22
0.64
39600
Current Ratio 15.42
ACAD's Current Ratio is ranked higher than
91% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. ACAD: 15.42 )
Ranked among companies with meaningful Current Ratio only.
ACAD' s Current Ratio Range Over the Past 10 Years
Min: 2.27  Med: 6.05 Max: 46.41
Current: 15.42
2.27
46.41
Quick Ratio 15.31
ACAD's Quick Ratio is ranked higher than
92% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. ACAD: 15.31 )
Ranked among companies with meaningful Quick Ratio only.
ACAD' s Quick Ratio Range Over the Past 10 Years
Min: 2.27  Med: 6.05 Max: 46.41
Current: 15.31
2.27
46.41
Days Inventory 381.67
ACAD's Days Inventory is ranked lower than
90% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. ACAD: 381.67 )
Ranked among companies with meaningful Days Inventory only.
ACAD' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 381.67
Current: 381.67
0
381.67
Days Sales Outstanding 260.16
ACAD's Days Sales Outstanding is ranked lower than
94% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. ACAD: 260.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACAD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 239.08  Med: 2932.17 Max: 9801.15
Current: 260.16
239.08
9801.15
Days Payable 752.90
ACAD's Days Payable is ranked higher than
99% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. ACAD: 752.90 )
Ranked among companies with meaningful Days Payable only.
ACAD' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 752.9
Current: 752.9
0
752.9

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.60
ACAD's 3-Year Average Share Buyback Ratio is ranked lower than
52% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. ACAD: -11.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ACAD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -153  Med: -24.1 Max: -2
Current: -11.6
-153
-2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.57
ACAD's Price-to-Net-Cash is ranked lower than
53% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. ACAD: 8.57 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ACAD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.69  Med: 4.92 Max: 19.49
Current: 8.57
0.69
19.49
Price-to-Net-Current-Asset-Value 8.35
ACAD's Price-to-Net-Current-Asset-Value is ranked lower than
56% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. ACAD: 8.35 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ACAD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.66  Med: 4.71 Max: 18.47
Current: 8.35
0.66
18.47
Price-to-Tangible-Book 8.25
ACAD's Price-to-Tangible-Book is ranked lower than
69% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ACAD: 8.25 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ACAD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.63  Med: 4.29 Max: 18.19
Current: 8.25
0.63
18.19
Price-to-Median-PS-Value 17.83
ACAD's Price-to-Median-PS-Value is ranked lower than
98% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. ACAD: 17.83 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ACAD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.61 Max: 649.2
Current: 17.83
0.02
649.2
Earnings Yield (Greenblatt) % -5.80
ACAD's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. ACAD: -5.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ACAD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.8  Med: 71.7 Max: 51153
Current: -5.8
-5.8
51153

More Statistics

Revenue (TTM) (Mil) $5.39
EPS (TTM) $ -2.14
Beta4.63
Short Percentage of Float30.92%
52-Week Range $17.02 - 42.49
Shares Outstanding (Mil)121.11

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 14 112 296 483
EPS ($) -2.22 -1.36 -0.02 1.12
EPS without NRI ($) -2.22 -1.36 -0.02 1.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)